■ INTRODUCTION
A significant fraction of currently used anticancer drugs are platinum compounds such as cisplatin, carboplatin (Paraplatin), and oxaliplatin (Eloxatin). 1 However their effectiveness is still hindered by clinical problems, including acquired or intrinsic resistance, a limited spectrum of activity, and high toxicity leading to side effects. 1, 2 The search for anticancer agents with improved properties has focused on the synthesis of a new generation of platinum compounds, 3,4 which include Pt(IV) pro-drugs, 5 multimetallic derivatives, 6 and the use of nanoparticles and oligonucleotides as delivery platforms. 7 The synthesis of other metallo drugs (including organometallic complexes) 8 of ruthenium, 9 gold, 10 titanium, 11 osmium, 12 copper, 13 rhodium, 14 iridium, 15 and iron 16 has also attracted great interest. More recently, a number of heterometallic cytotoxic complexes 17 have been reported, which show a synergic effect of two different metals with known antitumor properties. Palladium derivatives have been explored as an alternative 18 to platinum-based compounds due to the obvious structural and thermodynamic analogy between platinum(II) and palladium(II) complexes. However, the ligand-exchange kinetics of platinum(II) and palladium(II) derivatives are quite different; hydrolysis of palladium(II) compounds is much more rapid, leading to reactive species unable to reach their pharmacological targets. In addition, some Pd(II) compounds transform into inactive trans derivatives. The stabilization of Pd(II) compounds by strongly coordinated nitrogen ligands and an appropriate leaving group has been exploited as a synthetic strategy to obtain palladium(II) antitumor complexes. 18 Thus a variety of trans compounds containing bulky monodentate ligands, 19 complexes with bidentate ligands (N− N; P−P, or mixed N−O, N−S), 20 and organometallic derivatives 21 have been prepared. Since the seminal work by Navarro-Ranninger et al. on cytotoxic orthometalated palladium complexes 22 (some containing thiosemicarbazone ligands), a few cyclopalladated compounds with potential anticancer activities have been described. 23−25 The higher stability of cyclopalladated compounds in physiological media and a lower toxicity to normal cells are promising features for their biological applications. 18b Biphosphinic palladacycles of the type [Pd (C 2 ,N-(S (−) dmap)(dppf)]Cl induced apoptotic cell death in human leukemia cells by rupture of the lysosomal membrane and release of cathepsin B in the cytoplasm. 26−28 Importantly, the related compound [Pd 2 (S (−) C 2 ,N-dmpa) 2 (μ-dppe)Cl 2 ] has been selected for its promising antitumor properties against murine and cisplatin-resistant human tumor cells both in vitro and in vivo 29−31 for further preclinical studies, 30 including a gene therapy protocol in conjunction with plasmids. 31 Its mode of action seems to indicate DNA degradation and mitochondrial damage by interaction of the compound with thiol groups on the mitochondrial membrane proteins.
29,30
We have reported that nontoxic iminophosphorane or iminophosphine compounds serve as stabilizing (C,N-or N,N-) chelating ligands in the preparation of anticancer organometallic and coordination d 8 metal complexes.
32−34
Organogold(III) complexes containing iminophosphorane (C,N-IM) ligands of the type PPh 3 NPh displayed a high cytotoxicity in vitro against human ovarian cancer and leukemia cell lines 32, 33 while being less toxic to normal T-lymphocytes by a non-cisplatin mode of action (involving mitochondrial production of reactive oxygen species). 33 More recently, we have reported on the cytotoxicity of coordination Pd(II) and Pt(II) complexes with the first water-soluble iminophosphorane ligand, TPAN-C(O)-2-NC 5 H 4 (N,N-IM), described to date. 34 Interestingly, we found that the Pt(II) compound was more cytotoxic than cisplatin to leukemia cell lines (both TJurkat and cisplatin-resistant Jurkat sh-Bak) by a mode of action different from that of cisplatin. 34 The coordination Pd(II) derivative (slighty less cytotoxic than cisplatin to leukemia cell lines) displayed a mode of action similar to cisplatin. 34 We report here on the synthesis of a related water-soluble iminophosphorane ligand, TPAN-C(O)-2BrC 6 H 4 (1, C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane), which serves as an excellent precursor to organometallic Pd(II) derivatives with varying hydrophilic−lipophilic ratios. All new complexes have been tested as potential anticancer agents, and their cytotoxicity properties were evaluated in vitro against human Jurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC), and DU-145 human prostate cancer cells. The interactions of the most cytotoxic derivatives with plasmid (pBR322) DNA and human serum albumin (HSA) are reported.
■ RESULTS AND DISCUSSION 1. Synthesis and Characterization. Ligand 1, TPAN-C(O)-2BrC 6 H 4 , can be conveniently prepared from 2-bromobenzamide and TPA through the Pomerantz method (Scheme 1). 35 To the best of our knowledge, ligand 1 is one of the two examples of water-soluble iminophosphoranes prepared to date. 34 It is well known that most IMs in contact with water or polar solvents break down to the corresponding amine and phosphine oxide. 36 We have incorporated a CO group to stabilize the resulting water-soluble IM ligands. 
(L-L = acac (3); S 2 CNMe 2 (4); 4,7-diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt, C 12 H 6 N 2 (C 6 6 H 4 SO 3 Na) 3 (6); P(3-pyridyl) 3 (7)), and [Pd{C 6 H 4 (C-(O)NTPA)-2}(TPA) 2 Br] (8) are obtained (Scheme 2) in moderate to high yields (see Experimental Section). All complexes were characterized by means of NMR and IR spectroscopy, elemental analyses, mass spectrometry, and conductivity measurements (see Experimental Section). These techniques confirmed that the structures proposed for compounds 2−8 (Scheme 2) are the most plausible ones. In the case of the reactions of 2 with one neutral phosphine (v and vi in Scheme 2) the single isomer in which the incoming ligand is coordinated trans to the nitrogen atom (6 and 7) is obtained (typical reactivity of C,N-cyclopalladated halide dimers). 37 The reaction of 2 with TPA gives exclusively derivative [Pd-{C 6 H 4 (C(O)NTPA)-2}(TPA) 2 The most unstable complex is that with the bathophenanthroline ligand (5) , but this compound is stable under biological testing conditions (24 h). The crystal structure of 3 (determined by single-crystal X-ray diffraction study) is depicted in Figure 1 . Selected bond lengths and angles are collected in Table 1 . The geometry about the Pd(II) centers is pseudo-square-planar with the C(18)− Pd(1)−N(1) angle of 81. 35(16) o , suggesting a rigid "bite" angle of the chelating ligand. The Pd center is on an almost ideal plane with negligible deviations from the least-squares plane. The coordination plane for Pd and the metallocyclic plane are slightly twisted, to give an angle of 5.5°between them.
The main distances Pd−N(1) and Pd−C(18) of 2.037(4) and 1.966(4) Å found for 3 are a little shorter than or similar to those found in related carbonyl-stabilized iminophosphorane complexes where the cyclometalation occurs in the benzyl ring such as [Pd{C 6 H 4 (C(O)NP(p-tol) 3 -kC,N)-2}{acac-O,O′)] (2.0695(16) and 1.961(2) Å), 38 [Pd(μ-Cl){C 6 H 4 (C(O)N P(m-tol) 3 -kC,N)-2}] 2 (2.085(2) and 1.979(2) Å), 38 or {Pd(μ-Cl){C 6 H 3 (Me-3)(C(O)NPPh 3 -2}] 2 (2.043(2) and 1.962(3) Å). 39 The Pd1−O1 (2.023(3) Å) and Pd1−O2 (2.094(3) Å) bond distances fall in the usual range of distances found for chelating acac ligands. 38 The P ( 34 but considerably longer than in other semistabilized cyclopalladated complexes. 37 This elongation of the P−N bond is due not only to the coordination of the N atom to the palladium center but to the delocalization of charge density through the P−N−C−O system due to the presence of a CO group in the IM ligand. 37 2. Biological Activity. 2.1. Cytotoxicity Studies. Cytotoxicity results for ligand 1 and the new organometallic compounds (2−8) are collected in Table 2 . The IC 50 values for the decomposition product of ligand 1 (TPAO) are also collected for comparison purposes. The cytotoxicity (by a modification of the MTT-reduction method; see Experimental Section) was evaluated against two selected cell lines: human Jurkat-T acute lymphoblastic leukemia cells and DU-145 human prostate cancer cells. Cells were incubated in the presence of the compounds for 24 h. The sensitivity of T-cell leukemia Jurkat cells to compounds cisplatin, 1−8, and TPA O was compared to that of normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). Ligand 1 and the phosphine oxide TPA had IC 50 values greater than 500 μM in all cell lines studied and were considered as nontoxic. The more cytotoxic derivatives are the more lipophilic palladium complexes 2 and 3. This behavior has been also found for other cyclometalated compounds. 25a We expected that 4, with the chemoprotectant dithiocarbamate ligand, would display a higher cytotoxicity (as found for cycloaurated iminophosphorane complexes), 32 but this was not the case. In general the IC 50 values in DU145 are quite high and for 3 comparable to that of cisplatin ( ,N-dmpa)(dppf)]Cl. 27 Complexes 2 and 3 were 3 and 2 times more cytotoxic to T-cell leukemia Jurkat cells than the
34 Complexes 2 and 3 were 26 (2) or 11 times (3) less toxic to the normal lymphocytes (PMBC) than to the leukemia cell line. We have found, however, that cisplatin is 70 times less toxic to PMBC than to Jurkat cell lines. 34 We also studied the activity of compounds 2 and 3 and cisplatin against apoptosis-resistant cells (Figure 2 ). Multidomain proapoptotic proteins Bax and Bak are essential for the onset of mitochondrial permeabilization and apoptosis through the intrinsic pathway. Importantly, we observed that compounds 2 and, especially, 3 exhibited toxicity to cisplatinresistant Jurkat sh-Bak cells (Bax/Bak-deficient Jurkat cells). We have demonstrated previously that cisplatin at 25 μM caused the death of around 60% of Jurkat control (CN) cells, while Jurkat-shBak cells were very resistant to cisplatin (less than 8% death). 33 Figure 2 depicts that 2 and 3 (at 50 μM) caused the death of around 25% (2) and 75% (3) of JurkatshBak cells. This could be an advantage over cisplatin, whose activity is totally dependent on the presence of functional Bax and Bak.
Bax-independent apoptosis has been proposed as the death mechanism induced by a biphosphinic palladacycle complex in K562 leukemic cells. 27 Toxicity to Bax/Bak-deficient Jurkat cells has also been found for iminophosphorane organogold-(III) 33 and coordination Pt(II) complexes. 34 In contrast, the coordination palladium compound [PdCl 2 (TPAN-C(O)-2-NC 5 H 4 )] did not cause the death of Jurkat-shBak cells. 34 Cyclopalladation seems to have a positive effect on the cytotoxicity of IM-Pd complexes on cisplatin-sensitive and cisplatin-resistant leukemia cell lines. 2.2. Interactions of 2 and 3 with DNA and with Human Serum Albumin. Since DNA replication is a key event for cell division, it is among critically important targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with the DNA bases. 40 However, a variety of platinum compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands. 41 There are also reports on palladium derivatives interacting with DNA in covalent 42,43 and noncovalent ways. 22d, 44 We performed agarose gel electrophoresis studies on the effects of compounds 2 and 3 on plasmid (pBR322) DNA (Figure 3) . This plasmid has two main forms: OC (open circular or relaxed form, form II) and CCC (covalently closed or supercoiled form, form I).
Changes in electrophoretic mobility of both forms are usually taken as evidence of metal−DNA binding. Generally, the larger the retardation of supercoiled DNA (CCC, form I), the greater the DNA unwinding produced by the drug. 45 Binding of cisplatin to plasmid DNA, for instance, results in a decrease in mobility of the CCC form and an increase in mobility of the OC form (see lanes a, b, and c for cisplatin in Figure 3 ).
45
Treatment with increasing amounts of ligand 1 does not cause any shift for either form, consistent with no unwinding or other change in topology under the chosen conditions. Treatment with increasing amounts of compound 3 has a similar effect. Treatment with increasing amounts of compound 2 barely retards the mobility of the faster-running supercoiled form (form I) at high molar ratios (c) but to a much lesser extent than the retardation produced by cisplatin. Organogold(III) compounds containing iminophosphorane ligands did not interact with DNA. 32 Coordination iminophosphorane compounds of platinum(II) and palladium(II) of the type [MCl 2 (TPAN-C(O)-2-NC 5 H 4 )] showed a retardation of the faster-running supercoiled form (form I) especially at high molar ratios in a way different from that produced by cisplatin. 34 In conclusion, the experiments probing DNA−drug interactions showed that the new cyclopalladated iminophosphorane biologically active complexes have no (3) or very little (2) interaction with plasmid (pBR322) DNA, pointing to an alternative biomolecular target for these compounds. Mitochodrial damage by interaction of some cyclopalladated complexes containing phosphines with membrane proteins 26−28 and inhibition of cathepsin B 25, 26 have been reported as the plausible causes of their toxicity to cancer cell lines. In contrast, orthometalated complexes with thiosemicarbazones were found to have an enhanced capacity to form DNA interstrand crosslinks in comparison with cisplatin.
22e,f
Human serum albumin is the most abundant carrier protein in plasma and is able to bind a variety of substrates including metal cations, hormones, and most therapeutic drugs. It has been demonstrated that the distribution, the free concentration, and the metabolism of various drugs can be significantly altered as a result of their binding to the protein. 46 HSA possesses three fluorophores, these being tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe) residues, with Trp214 being the major contributor to the intrinsic fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding of substrates or changes in conformation that can result in quenching (either dynamic or static). The fluorescence spectra of HSA in the presence of increasing amounts of ligand 1, compounds 2−8, and cisplatin were recorded in the range 300−450 nm upon excitation of the tryptophan residue at 295 nm (Figure 4) . The compounds caused a concentrationdependent quenching of fluorescence without changing the emission maximum or shape of the peaks (2, 3, 6−8), as seen in Figure 4 for compound 3. For compound 5 a shift of the emission maximum was observed (from 340 to 390 nm). All these data indicate an interaction of the palladium compounds with HSA. The fluorescence data were analyzed by the Stern− Volmer equation. While a linear Stern−Volmer plot is indicative of a single quenching mechanism, either dynamic (Figure 4) is indicative of the presence of different binding sites in the protein. 47 In this graph higher quenching by the iminophosphorane complexes was observed compared to that of cisplatin under the chosen conditions. This is probably an indication of the faster hydrolysis in aqueous solution of our compounds compared to that of cisplatin.
We have found a similar behavior for coordination iminophosphorane complexes of d 8 metals, for which we also observed a concentration-dependent quenching. 34 In the case of [MCl 2 (TPAN-C(O)-2-NC 5 H 4 )] (M = Pd, Pt) isothermal titration calorimetry 34 showed two different binding interactions, which explained the lack of linearity observed in the fluorescence quenching studies, as the Stern−Volmer method assumes all binding sites to be equivalent. We believe that a similar behavior is observed for the cyclopalladated compounds described here. For [PtCl 2 (TPAN-C(O)-2-NC 5 H 4 )] we were able to demonstrate by circular dichroism studies that its binding to HSA was reversed by addition of a chelating agent (citric acid) and by a decrease in pH. In the case of the palladium compound 34 and compounds 2 and 3 described here, the CD reversibility experiments were not conclusive. Further analysis by a quantitative technique (atomic absorption spectrometry) is under way since studies of the reversibility of the binding of metallodrugs to HSA are very relevant to asses their potential efficacy in vivo.
■ CONCLUSION
We have prepared a new water-soluble iminophosphorane that serves as an excellent precursor to iminophosphorane cyclopalladated complexes with varying hydrophilic:lipophilic ratios stable in DMSO and DMSO−H 2 O solutions under biological testing conditions. We found that the most lipophilic compounds from the series, [Pd(μ-Br){C 6 H 4 (C(O)NTPA-kC,N)-2}] 2 (2) and [Pd{C 6 H 4 (C(O)NTPA-kC,N)-2}-(acac)] (3), display higher cytotoxicity against T-Jurkat leukemia cell while being less toxic to normal T-lymphocytes (PBMC). The IC 50 values were similar to those reported for other cyclopalladated compounds with promising antitumor properties and higher than an iminophosphorane coordination palladium complex, [PdCl 2 (TPAN-C(O)-2-NC 5 H 4 )], 34 previously described by us. Importantly, 2 and, especially, 3 showed toxicity against cisplatin-resistant Jurkat sh-Bak cells (Bax/Bak-deficient Jurkat cells). This could be an advantage over cisplatin, whose activity is totally dependent on the presence of functional Bax and Bak. It was demonstrated that these compounds have no (3) or very little (2) interaction with plasmid (pBR322) DNA, pointing to an alternative biomolecular target for their cytotoxic effect. All the compounds show an interaction with human serum albumin faster than that of cisplatin. We envision that an appropriate modification of IM ligands and subsequent orthopalladation can afford new cyclopalladated complexes with improved anticancer properties. In addition, some of the water-soluble nontoxic organometallic palladium complexes described here (such as [Pd{C 6 H 4 (C-(O)NTPA-kC,N)-2}(L)Br] (L = P(mC 6 H 4 SO 3 Na) 3 (6); P(3-Pyridyl) 3 (7)) could serve as precursors to stable homogeneous catalysts in water.
■ EXPERIMENTAL SECTION
All manipulations involving air-free syntheses were performed using standard Schlenk-line techniques under a nitrogen atmosphere or in a MBraun MOD System glovebox. Solvents were purified by use of a PureSolv purification unit from Innovative Technology, Inc. The substrates TPA and 4,7-diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt were purchased from Sigma-Aldrich, and Pd 2 (dba) 3 was purchased from Strem Chemicals and used without further purification. Phosphine P(3-pyridyl) 3 was prepared by a reported method. 48 Phosphine TPPTS P(mC 6 H 4 SO 3 Na) 3 was generously donated by Prof. LaśzlóT. Mika (Eoẗvos University, Budapest, Hungary). NMR spectra were recorded in a Bruker AV400 ( 1 H NMR at 400 MHz, 13 C NMR at 100.6 MHz, 31 ) were recorded on a Nicolet 6700 FT-IR spectrophotometer on KBr pellets. Elemental analyses were performed on a Perkin-Elmer 2400 CHNS/O analyzer, Series II. Mass spectra (ESI) were performed on an Agilent analyzer or a Bruker analyzer. Conductivity was measured in an OAKTON pH/conductivity meter in CH 3 CN, acetone, or H 2 O solutions (10 −3 M). Circular dichroism spectra were recorded using a Chirascan CD spectrometer equipped with a thermostated cuvette holder. Electrophoresis experiments were carried out in a Bio-Rad Mini subcell GT horizontal electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity measurements were carried out on a PTI QM-4/206 SE spectrofluorometer (PTI, Birmingham, NJ, USA) with rightangle detection of fluorescence using a 1 cm path length quartz cuvette.
Synthesis. TPAN-C(O)-2BrC 6 H 4 (C,N-IM) (1). TPA (0.157 g, 1.0 mmol) and 2-bromobenzamide (0.200 g, 1.0 mmol) were placed in a Schenck flask under nitrogen. Dry and degassed THF (15 mL) was added, and to this solution was added dropwise tBuDAD (0.230 g, 1.0 mmol) in dry and degassed THF (4 mL) at 0°C. The reaction was left stirring to warm for 15 h. After this period the yellow reaction mixture had become colorless. The solvent was reduced in vacuo to a minimum (<2 mL), and Et 2 O (10 mL) was added, giving a white solid, which was filtered off and dried in vacuo. Yield: 0.30 g (86%). Anal. Calcd for C 13 [Pd(μ-Br){C 6 H 4 (C(O)NTPA-kC,N)-2}] 2 (2) . To a suspension of Pd 2 (dba) 3 (0.457 g, 0.50 mmol) in dry and degassed CH 2 Cl 2 (15 mL) was added iminophosphorane 1 (0.354 g, 1.0 mmol), and the resulting mixture was stirred for 15 h at room temperature. The initial purple suspension evolved to a yellowish solution with some Pd 0 in suspension, which was filtered over Celite. The clear yellow solution was evaporated to a small volume (<2 mL), and Et 2 O (20 mL) was added. By continuous stirring, 2 was obtained as a yellow solid. Complex 2 was characterized by NMR as a mixture (1:1 molar ratio) of the geometric cis and trans isomers. Yield: 0.170 g (82% [Pd{C 6 H 4 (C(O)NTPA-kC,N)-2}(S 2 CNMe 2 )] (4). To a suspension of 2 (0.050 g, 0.054 mmol) in MeOH (35 mL) was added sodium dimethyldithiocarbamate as a solid. The suspension changed immediately from yellow to colorless. After stirring for 1 h at room temperature, the solvent was removed in vacuo to dryness. Acetone (35 mL) was added, and the resulting suspension was filtered through Celite to remove the NaBr formed. The solvent was reduced in vacuo to a minimum (∼2 mL), and Et 2 O (15 mL) was added, affording an off-white solid (4), which was filtered off and dried in vacuo. Yield: 0.047 g (79%). Anal. Calcd for C 16 [Pd{C 6 H 4 (C(O)NTPA-kC,N)-2}{C 12 H 6 N 2 (C 6 H 4 SO 3 Na) 2 }] (5). Sulfonated bathophenanthroline (0.059 g, 0.10 mmol) was dissolved in MeOH (3 mL) and the minimum amount of water to obtain a clear solution, which was then added slowly to a solution of 2 (0.046 g, 0.050 mmol) in CH 2 Cl 2 (7 mL). The resulting mixture was stirred for 1 h at rt, after which all solvents were evaporated to dryness. The resulting residue was redissolved in MeOH and filtered through Celite to remove the byproduct NaBr. The solvent was removed in vacuo, and the resulting pale yellow residue 5 was washed with Et 2 O, filtered off, and dried in vacuo. Yield: 0.072 g (78%). Anal. Calcd for C 39 [Pd{C 6 H 4 (C(O)NTPA-kC,N)-2}{P(mC 6 H 4 SO 3 Na) 3 }Br] (6). TPPTS (0.072 g, 0.128 mmol) was dissolved in MeOH (3 mL) and the minimum amount of water to obtain a clear solution, which was then added slowly to a solution of 2 (0.060 g, 0.064 mmol) in CH 2 Cl 2 (7 mL). The resulting mixture was stirred for 3 h at rt, after which all solvents were evaporated to dryness, and the residue was treated with Et 2 O (15 mL), affording 6 as an off-white solid, which was filtered off and dried in vacuo. Yield: 0.092 g (70%). Anal. Calcd for C 31 [Pd{C 6 H 4 (C(O)NTPA)-2}(TPA) 2 Br] (8). To a solution of 2 (0.060 g, 0.065 mmol) in CH 2 Cl 2 (7 mL) was added TPA (0.041 g, 0.261 mmol) as a solid. The reaction was left stirring at rt for 30 min, after which the solvent was reduced to a minimum and Et 2 O was added, affording an off-white solid (8) , which was filtered off and dried in v a c u o . Yield: 0.082 g (82%). Anal. Calcd for C 25 
